<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01712906</url>
  </required_header>
  <id_info>
    <org_study_id>FMumps-KMB17-I-IMB-CAMS</org_study_id>
    <nct_id>NCT01712906</nct_id>
  </id_info>
  <brief_title>A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children</brief_title>
  <official_title>A Phase II Clinical Trial for Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mumps is an acute infectious respiratory disease caused by the mumps virus (MuV), which&#xD;
      occurs mainly in children and adolescents. Its main clinical symptoms were parotid gland&#xD;
      suppurative swelling and pain with fever. The pathological changes and harm caused by mumps&#xD;
      was not only confined to the parotid gland, on the contrary, the social harm caused by&#xD;
      serious complications cannot be ignored. As mumps is a vaccine-preventable infectious&#xD;
      disease, vaccination is a fundamental strategy for controlling mumps. So far, there are 13&#xD;
      genotypes of MuV. Based on the analysis of molecular epidemiology, the main epidemic strain&#xD;
      of MuV in China was the F genotype. The commonly used vaccine strains represented only a&#xD;
      small number of known genotypes, e.g. Jeryl-Lynn (JL) and Rubini strains, which belong to&#xD;
      type A, Urabe strain belongs to type B, and L-Zagreb strains belongs to type D. Virus seed of&#xD;
      Live Attenuated Mumps Vaccine (Human diploid cell) developed by the institute was SP-A&#xD;
      strain, which was the first separation and preparation of the attenuated mumps viruses in&#xD;
      China. SP-A belongs to F genotype, which was the domestic epidemic genotype. In addition, the&#xD;
      cell substrate prepared for vaccine was human diploid cell (KMB-17 strain), which is much&#xD;
      safer to use. The preliminary test results showed that the vaccine possessed good&#xD;
      immunogenicity and good antigenic cross-reactivity. The application of this vaccine will&#xD;
      provide more effective means to prevent and control of mumps epidemic.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Safety of Attenuated Mumps Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults.</measure>
    <time_frame>within the first 28 days after the vaccination</time_frame>
    <description>Adverse reactions associated with vaccine were observed in Chinese Adults (from 16 to 59 years old) after the vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the Safety of Attenuated Mumps Vaccine (Human Diploid Cell, KMB-17) in Chinese Children.</measure>
    <time_frame>within the first 28 days after the vaccination</time_frame>
    <description>Adverse reactions associated with vaccine were observed in Chinese Children (from 5 to 15 years old) after the vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of Attenuated Mumps Vaccine (Human Diploid Cell, KMB-17) in Chinese Children.</measure>
    <time_frame>within the first 28 days after the vaccination</time_frame>
    <description>Adverse reactions associated with vaccine were observed in Chinese Children (from 2 to 4 years old) after the vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of Attenuated Mumps Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants.</measure>
    <time_frame>within the first 28 days after the vaccination</time_frame>
    <description>Adverse reactions associated with vaccine were observed in Chinese Infants (from 8 to 23 months old) after the vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the seroconversion rate of anti-Mumps antibodies in serum of adults, children and infants, after vaccination.</measure>
    <time_frame>within the first 28 days after the vaccination</time_frame>
    <description>The seroconversion rate of anti-MuV antibodies was evaluated in serum of adults at the 0 and 28 days after vaccination.&#xD;
The seroconversion rate of anti-MuV antibodies was evaluated in serum of children at the 0 and 28 days after vaccination.&#xD;
The seroconversion rate of anti-MuV antibodies was evaluated in serum of infants at the 0 and 28 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the abnormity change of live and kidney function indexes in serum of adults, children and infants, after vaccination</measure>
    <time_frame>within the first 4 days after the vaccination</time_frame>
    <description>The abnormity change of live and kidney function indexes were evaluated in serum of adults at 0, 4 days after vaccination.&#xD;
The abnormity change of live and kidney function indexes were evaluated in serum of children at 0, 4 days after vaccination.&#xD;
The abnormity change of live and kidney function indexes were evaluated in serum of infants at 0, 4 days after vaccination.</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>The Study Focused on the Safety of Attenuated Mumps Vaccine (Human Diploid Cell) Against Mumps in Chinese Adults, Children and Infants.</condition>
  <arm_group>
    <arm_group_label>3.50±0.25logCCID50/ml in adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 adults aged 16-59 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.25±0.25 logCCID50/ml in adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.00±0.25 logCCID50/ml in adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0 logCCID50/ml in adults</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 logCCID50/ml in 18 adults aged 16-59 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.50±0.25logCCID50/ml in children (5-15 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 5-15 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.25±0.25 logCCID50/ml in children (5-15 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.00±0.25 logCCID50/ml in children (5-15 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0 logCCID50/ml in children (5-15 years old)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 logCCID50/ml in 18 children aged 5-15 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.50±0.25logCCID50/ml in children (2-4 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 2-4 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.25±0.25 logCCID50/ml in children (2-4 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.00±0.25 logCCID50/ml in children (2-4 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0 logCCID50/ml in children (2-4 years old)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 logCCID50/ml in 18 children aged 2-4 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attenuated Mumps vaccine in children (2-4 years old)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 children aged 2-4 years old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.50±0.25logCCID50/ml in infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 infants aged 8-23 months old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4.25±0.25 logCCID50/ml in infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.00±0.25 logCCID50/ml in infants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0 logCCID50/ml in infants</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 logCCID50/ml in 18 infants aged 8-23 months old on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attenuated Mumps vaccine in infants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 infants aged 8-23 months old on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3.50±0.25logCCID50/ml</intervention_name>
    <description>Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.</description>
    <arm_group_label>3.50±0.25logCCID50/ml in adults</arm_group_label>
    <arm_group_label>3.50±0.25logCCID50/ml in children (2-4 years old)</arm_group_label>
    <arm_group_label>3.50±0.25logCCID50/ml in children (5-15 years old)</arm_group_label>
    <arm_group_label>3.50±0.25logCCID50/ml in infants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4.25±0.25 logCCID50/ml</intervention_name>
    <description>Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.</description>
    <arm_group_label>4.25±0.25 logCCID50/ml in adults</arm_group_label>
    <arm_group_label>4.25±0.25 logCCID50/ml in children (2-4 years old)</arm_group_label>
    <arm_group_label>4.25±0.25 logCCID50/ml in children (5-15 years old)</arm_group_label>
    <arm_group_label>4.25±0.25 logCCID50/ml in infants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>5.00±0.25 logCCID50/ml</intervention_name>
    <description>Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.</description>
    <arm_group_label>5.00±0.25 logCCID50/ml in adults</arm_group_label>
    <arm_group_label>5.00±0.25 logCCID50/ml in children (2-4 years old)</arm_group_label>
    <arm_group_label>5.00±0.25 logCCID50/ml in children (5-15 years old)</arm_group_label>
    <arm_group_label>5.00±0.25 logCCID50/ml in infants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0 logCCID50/ml</intervention_name>
    <description>0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.</description>
    <arm_group_label>0 logCCID50/ml in adults</arm_group_label>
    <arm_group_label>0 logCCID50/ml in children (2-4 years old)</arm_group_label>
    <arm_group_label>0 logCCID50/ml in children (5-15 years old)</arm_group_label>
    <arm_group_label>0 logCCID50/ml in infants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)</intervention_name>
    <description>Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.</description>
    <arm_group_label>Attenuated Mumps vaccine in children (2-4 years old)</arm_group_label>
    <arm_group_label>Attenuated Mumps vaccine in infants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects (8 months-59 years old) as established by medical history and&#xD;
             clinical examination&#xD;
&#xD;
          -  The subjects oneself or their legal guardian must be aware of this vaccines&#xD;
&#xD;
          -  Voluntarily participate in the study and signed Informed Consent Form&#xD;
&#xD;
          -  Subjects with temperature ≤ 37.0℃&#xD;
&#xD;
          -  With the ability and objective to comply with the requirements of the protocol&#xD;
&#xD;
          -  Persist for a 1-month visit and receive blood tests according to program requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who has a clinical diagnosis Mumps&#xD;
&#xD;
          -  Subject who vaccinated Mumps vaccine in last 6 months&#xD;
&#xD;
          -  ≤37 weeks gestation&#xD;
&#xD;
          -  weight ≤ 2500 g when it was born&#xD;
&#xD;
          -  Allergy or serious side-effects to a vaccine or any ingredient of vaccine&#xD;
&#xD;
          -  Epilepsy, seizures, convulsions, neurological illness&#xD;
&#xD;
          -  Congenital or hereditary immunodeficiency&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Severe malnutrition or dysgenopathy&#xD;
&#xD;
          -  Asthma, thyroidectomy, angioneurotic edema, diabetes or cancer&#xD;
&#xD;
          -  Asplenia, functional asplenia, and any circumstances leading to the asplenia or&#xD;
             splenectomy&#xD;
&#xD;
          -  Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation&#xD;
             disorders, platelet abnormalities), significant bruising or blood clotting disorder&#xD;
&#xD;
          -  Acute illness or acute exacerbation of chronic disease in last 7 days&#xD;
&#xD;
          -  Any prior administration of immunodepressant or corticosteroids in last 6 months&#xD;
&#xD;
          -  Any prior administration of blood products in last 3 months&#xD;
&#xD;
          -  Any prior administration of live-attenuated vaccine in last 28 days or 1 months&#xD;
&#xD;
          -  Any prior administration of subunit or inactivated vaccines in last 14 days&#xD;
&#xD;
          -  Under the anti-TB prevention or therapy&#xD;
&#xD;
          -  Fever before vaccination, axillary temperature ﹥37.0℃&#xD;
&#xD;
          -  The laboratory test abnormalities before vaccination, including blood tests&#xD;
             (hemoglobin, total white blood cells, WBC, platelets), blood biochemistry tests (ALT,&#xD;
             total bilirubin, direct bilirubin, Cr, BUN) and urine tests (urine protein, urine&#xD;
             sugar, blood cells), etc.&#xD;
&#xD;
          -  Hypertension or hypotension. Systolic blood pressure ﹥140mmHg and/or diastolic blood&#xD;
             pressure ﹥90mmHg; systolic blood pressure ﹤90mmHg and/or diastolic blood pressure&#xD;
             ﹤60mmHg&#xD;
&#xD;
          -  Breast-feeding, pregnant, planning a pregnancy within 60 days or positive pregnancy&#xD;
             test women&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator, may interfere with the&#xD;
             evaluation of study objectives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Months</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuliang Zhao, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Provincial Center for Diseases Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hebei Provincial Center for Diseases Control and Prevention</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 22, 2012</study_first_submitted>
  <study_first_submitted_qc>October 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>April 26, 2013</last_update_submitted>
  <last_update_submitted_qc>April 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Longding Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mumps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

